Accordingly, A2AR antagonists are currently being explored in clinical trials as coadjuvants for autoimmune transplantation therapies for immunogenic cancers (NCT05024097, https://clinicaltrials.gov/ct2/show/NCT05024097?term=adenosine+receptor&cond=cancer&draw=2&rank=1). Here, ADORA2A is linked to cancer.